Research Study Summary
A multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients
The purpose of the study to evaluate the efficacy, safety and tolerability of intravenous infusion of serelaxin, when added to standard therapy, in acute heart failure (AHF) patients.
To Learn more
CW ID: 203072
Date Last Changed:
November 6, 2014
Clinical Trial Snapshot
- Both Male and Female
- 18 and up
- Overall Status
- Novartis Pharmaceuticals Corporation
- Facility Type
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.